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A 65-year-old Japanese male with type 2 diabetes mellitus was admitted to our hospital with a pro-
ductive cough and worsening dyspnea. He had started receiving vildagliptin, which is one of the
dipeptideylpeptidase-4 (DPP-4) inhibitors, several days before the appearance of his symptoms. Labo-
ratory ﬁndings revealed markedly elevated levels of immunoglobulin E and Krebs von den Lungen-6.
Chest computed tomography revealed ground-glass opacity with irregular reticulation throughout
both lungs. Biopsy specimens by transbronchial lung biopsy showed subacute interstitial pneumonia and
an organizing pneumonia pattern with acute alveolar injury. The drug lymphocyte stimulation test
showed a positive result for vildagliptin. Withdrawal of vildagliptin and administration of glucocorticoid
treatment improved his respiratory condition and radiological ﬁndings. Therefore, we diagnosed the
patient with vildagliptin-induced interstitial pneumonia based on both his clinical course and patho-
logical ﬁndings. Interstitial pneumonia as a side effect of vildagliptin is rare. It may be necessary to
monitor the respiratory condition of patients upon administration of DPP-4 inhibitors until further ev-
idence is obtained.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Type 2 diabetes mellitus (T2DM) is one of the most challenging
health-care problems, and novel therapeutic strategies are neces-
sary. Vildagliptin, one of the dipeptidyl peptidase (DPP)-4 in-
hibitors, is an oral anti hyperglycemic agent that enhances insulin
secretion in a glucose-dependent manner and has been widely
used in the management of T2DM. The known side effects of vil-
dagliptin are hypersensitivity reactions, including skin disorders,
hepatic toxicity and so forth [1]. Drug-induced lung injury
including interstitial pneumonia associated with vildagliptin has
rarely been reported. We here describe, to the best of our knowl-
edge, the ﬁrst case of interstitial pneumonia in a Japanese patientomputed tomography; DLST,
peptidase-4; FVC, forced vital
neumonia with autoimmune
nary function testing; TBLB,
ellitus.
Ltd. This is an open access article ureceiving vildagliptin.2. Case report
A 65-year-old Japanesemalewas admitted to our hospital with a
productive cough and progressive dyspnea. His comorbidities were
hypertension and T2DM; therefore, he regularly received some
medications. Several days before the appearance of his chief com-
plaints, vilidagliptin (100 mg/day) was started for uncontrolled
T2DM. His respiratory condition gradually worsened over about
two weeks.
On hospital admission, his vital signs were as follows: body
temperature 35.8 C, blood pressure 120/79 mmHg, heart rate 66
bpm, and oxygen saturation 98% under 2 L/min of oxygen. On
physical examination, the patient had ﬁne crackles in both lung
ﬁelds on chest auscultation. There were no physical signs sugges-
tive of collagen vascular diseases. The laboratory tests showed high
levels of serum immunoglobulin E (IgE: 4216 mg/dl, normal
range<400 mg/dl) and Krebs von den Lungen-6 (KL-6: 9781 U/ml,
normal range<500 U/ml). Examination of autoantibody titers,
including anti-nuclear antibody, anti-ribonucleoprotein antibody,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. (a) Chest X-ray picture on admission. Reduction of lung volume and reticular shadows were observed bilaterally. (b and c) Chest computed tomography showed extensive
ground-glass opacity including irregular reticular opacity in both lung ﬁelds. The distribution of interstitial shadows was peribronchovascular and basal dominant.
Fig. 2. Pathological ﬁndings of biopsy specimens. (a) Atypical and multinucleated
regenerating alveolar epithelial cells are found. Eosinophils, lymphocytes and plasma
cells have inﬁltrated the lungs (Hematoxylin and Eosin staining). (b) Dense air space
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bodies, as well as anti centromere antibody, anti-topoisomeraseI
antibody, anti t-RNA synthetase antibody and serum complement,
demonstrated that all were within normal range. Arterial blood gas
analysis on 2 L/min of oxygen revealed respiratory alkalosis (pH:
7.450, PaO2: 111.6 Torr, PaCO2: 32.1 Torr, HCO3: 21.8 mmol/L). A
chest radiograph showed reduction of bilateral lung-volume and
reticular shadows in all lung ﬁelds (Fig. 1a). Chest computed to-
mography (CT) demonstrated extensive ground-glass opacity
(GGO) with associated irregular reticulation throughout both lungs.
The distribution of interstitial shadows was peribronchovascular
and basal dominant (Fig. 1b and c). Pulmonary function test (PFT)
revealed a restrictive defect; forced vital capacity (FVC) was 43.2%
of the predicted value. Flexible bronchoscopy showed normal
airway anatomy. Bronchoalveolar lavage (BAL) ﬂuid revealed in-
ﬂammatory changes with a cell differential count of 23% macro-
phages, 57% lymphocytes, 5% neutrophils, and 12% eosinophils.
Microbiological studies of BAL ﬂuid were negative. Transbronchial
lung biopsy (TBLB) was performed and biopsy samples were ob-
tained from both the left upper and lower lobes. Biopsy specimens
of the lung showed atypical and multinucleated regenerative
alveolar epithelial cells, and inﬁltration of eosinophils, lymphocytes
and plasma cells was observed (Fig. 2a). Interstitial ﬁbrosis was
seen both in the alveoli and around the thickened alveolar walls
(Fig. 2b). These ﬁndings of TBLB specimens were consistent with
subacute interstitial pneumonia, which is an organizing pneumonia
with an acute alveolar injury pattern. In addition, the drug
lymphocyte stimulation test (DLST) for vildagliptin was positive.
From these results, we diagnosed the patient as having vildagliptin-
induced interstitial pneumonia.
Vildagliptin was discontinued on the day that the patient was
admitted (day 20) and glucocorticoid therapy was initiated on day
27 (Fig. 3). The respiratory condition and GGO ﬁndings on chest CT
gradually improved after glucocorticoid treatment was started. The
patient was discharged on day 75. The patient continues to take his
regular his regular medications except vildagliptin, and has had no
recurrence.aggregates are present and stained blue, which indicated the subacute phase of the
disease (Alcian-blue-PAS staining).
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Fig. 3. Clinical course of the patient. After cessation of vildagliptin and initiation of glucocorticoid therapy, the patient's respiratory symptoms and GGO ﬁndings on chest CT
gradually improved. Serum KL-6 and IgE levels also improved.
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We herein described a very rare case of vildagliptin-induced
interstitial pneumonia. To the best of our knowledge, there is no
case report of vildagliptin-induced interstitial pneumonia in
PubMed, U.S. Food and Drug Administration (FDA) and Pneumo-
tox®. According to the ICHUSHI website, the database of Japanese
articles, one case of pneumonitis induced by vildagliptin has been
reported in the Japanese literature [2]. In addition, safety infor-
mation by the Pharmaceuticals and Medical Devices Agency
(PMDA) in Japan suggested the association between vildagliptin
and lung injury among Japanese people [3].
Little is known about the mechanism by which DPP-4 inhibitors
including vildagliptin induce lung injury. DPP-4, also identiﬁed as
CD26 antigen, is a type II trans-membrane glycoprotein that is
constitutively expressed on activated lymphocytes and in lung
parenchyma including endothelial cells and ﬁbroblasts [4]. The
effect of CD26/DPP-4 inhibitors on lung inﬂammation and ﬁbrosis
has not been fully investigated.
Stephan et al. reported [5] that continuous DPP-4 inhibition by
oral administration could aggravate allergic inﬂammation of the
airway; however, topical inhibition of DPP-4 by aerosolization had a
beneﬁcial effect on allergic symptoms in mice. On the other hand,
Jungraithmay et al. [6] reported that CD26/DPP-4 inhibition
recruited regenerative stem cells to the lungs and beneﬁcially
inﬂuenced ischemia-reperfusion lung injury after lung trans-
plantation in mice. They demonstrated that DPP-4 inhibition
increased the level of stromal cell-derived factor-1 (SDF-1) in
plasma and the lungs together with up-regulation of its receptor
CXC4. The SDF-1-CXCR4 axis improved engraftment of stem cells
following tissue injury [6]. Recently, Sada et al. [7] reported a case of
sarcoid-like lung granulomas following the administration of vil-
dagliptin. The granuloma lesions disappeared after discontinuation
of vildagliptin. The relationship between DPP-4 inhibition andgranuloma formation in the lungs is unclear. The effect of a DPP-4
inhibitor on inﬂammation or immune system of the lungs is un-
clear and further studies are necessary.
As is well known, there is no speciﬁc clinical, radiological, or
pathological feature for the diagnosis of drug-induced lung injury
[8]. In the present case, it is clear that respiratory symptoms had
been recognized several days after administration of vildagliptin
and gradually worsened over two weeks. His symptoms and
radiological ﬁndings recovered following the withdrawal of vilda-
gliptin and administration of glucocorticoid. Pathological ﬁndings
of lung specimens obtained by TBLB showed sub-acute interstitial
pneumonia and organizing pneumonia with an acute alveolar
injury pattern consistent with drug-induced lung injury. Of course
the ﬁndings of chest CT in this casemay be almost indistinguishable
from those of interstitial pneumonia with autoimmune features
(IPAF) but the pathologic ﬁndings were decisively different from
those of IPAF. That is to say, inﬁltration of eosinophils and acute
alveolar injury pattern were observed. These ﬁndings do not meet
the diagnostic criteria for nonspeciﬁc interstitial pneumonia (NSIP)
[9,10]. Moreover, the result of the DLST for vildagliptinwas positive.
The DLST is not particularly accurate, and compelling evidence
about the sensitivity and speciﬁcity of diagnosing drug-induced
lung (DILD) injury has not been obtained. Therefore, it is indis-
putable that DILD injury should be diagnosed by exclusion of other
diseases based on the patient's clinical course, laboratory data and
imaging results [11]. Therefore, we diagnosed the present case with
vildagliptin-induced interstitial pneumonia. Although the drug re-
challenging test is recommended if possible, we did not believe that
re-challenging of vildagliptin was safe in the present case.
In conclusion, we reported a very rare case of vildagliptin-
induced interstitial pneumonia. To the best of our knowledge, this
is the ﬁrst report of vildagliptin-induced interstitial pneumonia
that was diagnosed based on both the patient's clinical course and
pathological ﬁndings.
N. Kuse et al. / Respiratory Medicine Case Reports 18 (2016) 10e13 13Our purpose of reporting the present case is to alert physicians
that they may encounter such unexpected adverse events in pa-
tients undergoing vildagliptin therapy. Accumulation of cases and
further research are necessary in order to determine the mecha-
nism of lung injury and predictable risk factors.
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